Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Ophthalmology

Free Subscription Articles published in J Ocul Pharmacol Ther Retrieve available abstracts of 155 articles: HTML format

Single Articles

March 2026
1. CHANG YC, Yang YC, Chen PH, Wu WC, et al
   All-Trans Retinoic Acid Modulates MicroRNA-129-5p/Hypoxia-Inducible Factor-1alpha/Vascular Endothelial Growth Factor Signaling and Suppresses Ets-1 in Retinal Pigment Epithelial ARPE-19 Cells.
   J Ocul Pharmacol Ther. 2026 Mar 23:10807683261434410.
   PubMed     Abstract available
   
   
   
2. ZHENG Y, Jiang H, Wang J, Zhang Q, et al
   AG1295 Attenuates High-Glucose-Induced Proliferation, Migration, Phenotype Transition, and Interleukin-6 Expression in Human Corneal Stromal Fibroblasts.
   J Ocul Pharmacol Ther. 2026 Mar 18:10807683261433333.
   PubMed     Abstract available
   
   
   
3. FUNG SSM, Campos C, Weiss J, Yermilov I, et al
   Systematic Literature Review on the Effect of Cenegermin on Corneal Sensation and Innervation in Patients with Neurotrophic Keratopathy.
   J Ocul Pharmacol Ther. 2026 Mar 18:10807683261429005.
   PubMed     Abstract available
   
   
   
4. CELIK E, Polat E, Guven F, Yilmaz A, et al
   Vitreous and Serum Levels of IL-1beta and IL-33 in Proliferative Diabetic Retinopathy: Evaluation of Local Versus Systemic Inflammatory Signatures.
   J Ocul Pharmacol Ther. 2026 Mar 17:10807683261433766.
   PubMed     Abstract available
   
   
   
5. BISWAL S, Das D, Sahoo RN, Parmanik A, et al
   New In Situ Gel Eye Formulation Based on Aristoflex and Xanthan Gum in the Management of Glaucoma Disease: Nonclinical Studies.
   J Ocul Pharmacol Ther. 2026 Mar 14:10807683261428957.
   PubMed     Abstract available
   
   
   
6. KRAMM RL, Novack GD
   Basis of Approval for Glaucoma Drugs and Devices: 2003-2025.
   J Ocul Pharmacol Ther. 2026 Mar 1:10807683261422104.
   PubMed    
   
   
   
7. CHEN KY, Chan HC, Chan CM
   Is Methotrexate a Superior Alternative to Steroids or Placebo for Scleritis? A Systematic Review and Meta-Analysis on Efficacy and Safety.
   J Ocul Pharmacol Ther. 2026;42:117-128.
   PubMed     Abstract available
   
   
   
8. YAO Y, Wang Y, Chen L, Guo M, et al
   Drug Repurposing of Octreotide as a Selective Apelin Receptor Antagonist Against Pathological Angiogenesis: Integrated Virtual Screening and Zebrafish Validation.
   J Ocul Pharmacol Ther. 2026;42:139-147.
   PubMed     Abstract available
   
   
   February 2026
9. MACHADO LF, Kawamuro M, Bando A, Sokabe L, et al
   Fixed Triple-Combination Bimatoprost/Brimonidine/Timolol Versus Separate Administration in Glaucoma: Randomized Clinical Trial.
   J Ocul Pharmacol Ther. 2026 Feb 25:10807683261421428.
   PubMed     Abstract available
   
   
   
10. YAN B, Wu SN, Chen XD, Yang ZX, et al
    Drug-Related Uveitis: A Real-World Study Based on the Food and Drug Administration Adverse Event Reporting System Database.
    J Ocul Pharmacol Ther. 2026 Feb 24:10807683261421744.
    PubMed     Abstract available
    
    
    
11. TUNON-ROBINSON I, Zhang R, Nguyen AK
    Visual Acuity Outcomes Following Intravitreal Biological Drug-Induced Retinal Vasculitis: An Intelligent Research in Sight Registry Retrospective Exploratory Analysis.
    J Ocul Pharmacol Ther. 2026 Feb 10:10807683251412321.
    PubMed     Abstract available
    
    
    
12. SUSANNA CN, Martines C, Susanna FN, Germano R, et al
    Evaluation of Peak Intraocular Pressure Reduction in the Water-Drinking Test and Safety of Subliminal Subthreshold Laser.
    J Ocul Pharmacol Ther. 2026 Feb 4:10807683261417554.
    PubMed     Abstract available
    
    
    January 2026
13. LABETOULLE M, Benitez Del Castillo JM, Ucakhan-Gunduz O, Boboridis K, et al
    Comparison of Two Preservative-Free Artificial Tears with Sodium Hyaluronate for Relief of Dry Eye Symptoms: A Randomized, Investigator-Masked Study.
    J Ocul Pharmacol Ther. 2026;42:30-37.
    PubMed     Abstract available
    
    
    
14. LANTYER-ARAUJO NL, Park S, Hisey EA, Thomasy SM, et al
    Topical Application of a Novel Harderian-Derived Nonpolar Lipid Prolongs Tear Film Breakup Time in Normal Beagle Dogs.
    J Ocul Pharmacol Ther. 2026;42:38-44.
    PubMed     Abstract available
    
    
    
15. EL-HARAZI SM, Peace JH, Nguyen A, Yuan J, et al
    Safety and Efficacy of AGN-241622 for Presbyopia: Results From a First-in-Human, Phase 1/2, Randomized, Vehicle-Controlled Study.
    J Ocul Pharmacol Ther. 2026;42:21-29.
    PubMed     Abstract available
    
    
    December 2025
16. NGUYEN A, Ramer EB, Robinson MR
    Corneal Endothelial Cell Loss From Anterior Chamber Paracentesis in a Porcine Model.
    J Ocul Pharmacol Ther. 2025 Dec 18. doi: 10.1177/10807683251408349.
    PubMed     Abstract available
    
    
    
17. FINK MK, Gupta S, Kumar R, Sinha PR, et al
    Topical Rho-Associated Protein Kinase Inhibitor HA1077 Reduces Rabbit Corneal Fibrosis and Neovascularization in Vivo.
    J Ocul Pharmacol Ther. 2025 Dec 18. doi: 10.1177/10807683251405622.
    PubMed     Abstract available
    
    
    
18. SHARIF NA, Kulkarni-Chitnis M, Okolie A, Chaudhry SD, et al
    Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation.
    J Ocul Pharmacol Ther. 2025 Dec 12. doi: 10.1177/10807683251405992.
    PubMed     Abstract available
    
    
    
19. PARK JH, Son Y, Park CY
    Cetalkonium Chloride Induced a Dose-Dependent Toxicity on Corneal Endothelial Cells.
    J Ocul Pharmacol Ther. 2025 Dec 12. doi: 10.1177/10807683251405795.
    PubMed     Abstract available
    
    
    
20. MAKI K, Kimura E, Yamamoto Y, Fuwa M, et al
    The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys.
    J Ocul Pharmacol Ther. 2025 Dec 12. doi: 10.1177/10807683251401740.
    PubMed     Abstract available
    
    
    November 2025
21. SHETTLE L, Mulaney J, Williams RD, Beck J, et al
    Double-Masked Controlled Trial of H-1337 as a Treatment for Glaucoma and Ocular Hypertension.
    J Ocul Pharmacol Ther. 2025 Nov 4. doi: 10.1177/10807683251393984.
    PubMed     Abstract available
    
    
    
22. DU J, Rong Y, Yu Z, Li Y, et al
    Effects of Intense Pulsed Light Treatment Combined with Meibomian Gland Expression on Post-Laser Corneal Refractive Surgery Dry Eyes.
    J Ocul Pharmacol Ther. 2025 Nov 4. doi: 10.1177/10807683251391082.
    PubMed     Abstract available
    
    
    
23. WU J, Wu H, Zhou B, He X, et al
    Effect of Topical Application of Dexamethasone on CC Chemokine Receptor 3 Expression in Human Pterygium.
    J Ocul Pharmacol Ther. 2025;41:530-543.
    PubMed     Abstract available
    
    
    
24. 
    Corrigendum to: "The Endocannabinoid System: Role in Ocular Physiology and Therapeutic Potential in Eye Diseases: A Narrative Review".
    J Ocul Pharmacol Ther. 2025;41:554.
    PubMed    
    
    
    October 2025
25. LI A, Chang X, Pu Q, Guo X, et al
    Ambroxol is Effective for Corneal Pain in Rats.
    J Ocul Pharmacol Ther. 2025 Oct 27. doi: 10.1177/10807683251391936.
    PubMed     Abstract available
    
    
    
26. ZHOU L, Qin T, Lv Y, Wu Z, et al
    Qiming Granules Ameliorate Diabetic Retinopathy by Regulating the PI3K/Akt Signaling Pathway.
    J Ocul Pharmacol Ther. 2025 Oct 24. doi: 10.1177/10807683251390213.
    PubMed     Abstract available
    
    
    
27. SHARIF NA, Ota T, Taniguchi T, Sasaoka M, et al
    Cutamesine (SA4503) Protects Retinal Ganglion Cells in an Ocular Hypertension Model of Glaucoma Determined Using Detection of Apoptosing Retinal Cells Technology and RBPMS Cell Marker.
    J Ocul Pharmacol Ther. 2025 Oct 24. doi: 10.1177/10807683251389754.
    PubMed     Abstract available
    
    
    
28. HIRUNPATRAVONG P, Uramphorn N, Kasemsup T, Caprioli J, et al
    Comparison of Preoperative Subconjunctival Injection, Intraoperative Subconjunctival Injection, and Soaked Sponges as Mitomycin C Delivery Methods for Trabeculectomy with a 6-Month Follow-Up Period: A Randomized Controlled Pilot Study.
    J Ocul Pharmacol Ther. 2025 Oct 22. doi: 10.1177/10807683251391092.
    PubMed     Abstract available
    
    
    
29. GUPTA S, Kumar R, Tripathi R, Sinha NR, et al
    Carbofuran Exposure Alters Autophagy Flux in Human Cornea In Vitro and Ex Vivo.
    J Ocul Pharmacol Ther. 2025 Oct 20. doi: 10.1177/10807683251388753.
    PubMed     Abstract available
    
    
    
30. ZHOU Z, Zhu J, Deng W, Zhang F, et al
    Mechanisms Underlying the Protective Effects of Piperine on Retinal Pigment Epithelium Cells.
    J Ocul Pharmacol Ther. 2025 Oct 13. doi: 10.1177/10807683251383712.
    PubMed     Abstract available
    
    
    
31. CHEN Y, Zhang S, Zhong Q, Chen S, et al
    Inflammatory Proteins Profiling in Tear Fluid in Polypoidal Choroidal Vasculopathy and Neovascular Age-Related Macular Degeneration.
    J Ocul Pharmacol Ther. 2025 Oct 9. doi: 10.1177/10807683251384447.
    PubMed     Abstract available
    
    
    
32. AL-DWAIRI R, Ahmad AA, Aleshawi A, Al-Bataineh QM, et al
    Associations Between Clinical Parameters and Optical-Physicochemical Properties of Silicone Oil Extracted after Pars Plana Vitrectomy: An In Vitro Analysis of 35 Eyes.
    J Ocul Pharmacol Ther. 2025 Oct 3. doi: 10.1177/10807683251386127.
    PubMed     Abstract available
    
    
    
33. MA H, Liu D, Tang X, Fu Y, et al
    Baicalein in Ophthalmology: Recent Progress and Emerging Therapeutic Applications.
    J Ocul Pharmacol Ther. 2025 Oct 3. doi: 10.1177/10807683251370549.
    PubMed     Abstract available
    
    
    September 2025
34. DMUCHOWSKA DA, Godzien J, Mojsak P, Godlewski A, et al
    Comment on: Changes in Aqueous Humor Cytokines and Metabolomics in Contralateral Eye After Unilateral Cataract Surgery.
    J Ocul Pharmacol Ther. 2025 Sep 19. doi: 10.1177/10807683251380991.
    PubMed     Abstract available
    
    
    
35. RASSI TNO, Amaral DC, Mund E, Pimentel ALM, et al
    Assessing Long-Term Feasibility and Efficacy of Treatments for Retinal Vein Occlusion Macular Edema: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
    J Ocul Pharmacol Ther. 2025 Sep 18. doi: 10.1177/10807683251380974.
    PubMed     Abstract available
    
    
    
36. ZENG F, He H, Huang S, Luo Y, et al
    Brimonidine Topical Eye Drops and Intravitreal Administration Inhibit Form-Deprivation Myopia in Guinea Pigs: Ocular Pharmacokinetics and Irritation.
    J Ocul Pharmacol Ther. 2025 Sep 18. doi: 10.1177/10807683251376438.
    PubMed     Abstract available
    
    
    
37. LEE H, Sharma A, Woo SJ
    Clinical Trials of Aflibercept Biosimilars: A Review.
    J Ocul Pharmacol Ther. 2025;41:363-369.
    PubMed     Abstract available
    
    
    
38. KHOLZODA S, Ozkan G, Dericioglu V, Akkaya Turhan S, et al
    Topical Cyclosporine and Steroid Treatments: A Comparative Approach to Membranous Punctal Stenosis.
    J Ocul Pharmacol Ther. 2025;41:387-396.
    PubMed     Abstract available
    
    
    August 2025
39. YILDIRIM H, Balbaba M, Canleblebici M, Dal A, et al
    Effect of Dasatinib on Oxidative Stress and Neovascularization in Experimental Corneal Neovascularization.
    J Ocul Pharmacol Ther. 2025 Aug 21. doi: 10.1177/10807683251370551.
    PubMed     Abstract available
    
    
    
40. FEKI O, Zhioua-Braham I, Haddar S, Arfaoui A, et al
    The Endocannabinoid System: Role in Ocular Physiology and Therapeutic Potential in Eye Diseases: A Narrative Review.
    J Ocul Pharmacol Ther. 2025 Aug 21. doi: 10.1177/10807683251368650.
    PubMed     Abstract available
    
    
    
41. SHEN M, Xu B
    Rosmarinic Acid Mitigates Lipopolysaccharide-Induced Inflammation and Oxidative Stress in Human Corneal Epithelial Cells as an In Vitro Keratitis Cell Model.
    J Ocul Pharmacol Ther. 2025 Aug 15. doi: 10.1177/10807683251366780.
    PubMed     Abstract available
    
    
    
42. NORK TM, Katz AW, Rasmussen CA, Kim CBY, et al
    Custom-Made Injector for Suprachoroidal Ocular Delivery: Effect of Intraocular Pressure, Volume, and Location on the Distribution of Aqueous Solutions in Rabbits.
    J Ocul Pharmacol Ther. 2025 Aug 8. doi: 10.1177/10807683251366799.
    PubMed     Abstract available
    
    
    
43. LEI J, Zeng L, Gao X, Wang D, et al
    Comparison of Topical Gatifloxacin and Levofloxacin at Different Durations in Eliminating Conjunctival Bacterial Flora.
    J Ocul Pharmacol Ther. 2025 Aug 6. doi: 10.1177/10807683251366114.
    PubMed     Abstract available
    
    
    
44. XIA R, Lin L, Liu Z, Chen W, et al
    Nonsurgical Therapies for Preventing Corneal Scarring: A Systematic Review of the Past Decade.
    J Ocul Pharmacol Ther. 2025 Aug 6. doi: 10.1177/10807683251361725.
    PubMed     Abstract available
    
    
    
45. KHAN H, Aftab OM, Billah MS, Khouri AS, et al
    Beyond the Prostate: A Visionary Study on Ocular Impacts of Benign Prostatic Hyperplasia Drugs.
    J Ocul Pharmacol Ther. 2025 Aug 6. doi: 10.1089/jop.2025.0030.
    PubMed     Abstract available
    
    
    
46. WANG Z, Li G, Lu H, Wang J, et al
    The Efficacy and Safety of Tumor Necrosis Factor alpha Inhibitors in the Treatment of Noninfectious Uveitis: A Systematic Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2025 Aug 5. doi: 10.1177/10807683251363436.
    PubMed     Abstract available
    
    
    
47. MONTMEAT D, Thouvenin A, Rasamison R, Boudy V, et al
    Physicochemical Properties and Rheological Behavior of Artificial Tears for Dry Eye Syndrome.
    J Ocul Pharmacol Ther. 2025 Aug 5. doi: 10.1177/10807683251364169.
    PubMed     Abstract available
    
    
    
48. CHOUDHRY HS, Pei M, Mothy D, Scarfuto J, et al
    Real-World Safety Profile of Cenegermin Per FDA Adverse Event Reporting System.
    J Ocul Pharmacol Ther. 2025;41:339-346.
    PubMed     Abstract available
    
    
    July 2025
49. ROJAS R, Hinkle DM
    Infectious, Immune-Mediated, and Vaccine-Associated Ocular Adverse Events.
    J Ocul Pharmacol Ther. 2025 Jul 30. doi: 10.1177/10807683251363420.
    PubMed    
    
    
    
50. HERBOTS H, Van Os L, Aerts W, Tassignon MJ, et al
    Evaluation of Systemic Exposure to Intracameral Tropicamide 0.02%, Phenylephrine 0.31%, and Lidocaine 1% in Pediatric Cataract Surgery.
    J Ocul Pharmacol Ther. 2025 Jul 18. doi: 10.1177/10807683251359451.
    PubMed     Abstract available
    
    
    
51. ZHOU J, Wang D, Li GC, Huang Q, et al
    GCN5-TFEB Pathway Regulates Inflammation by Tuning Autophagic Degradation of Retinoic Acid-Induced Gene-I in Human Conjunctival Epithelial Cells.
    J Ocul Pharmacol Ther. 2025 Jul 9. doi: 10.1089/jop.2025.0029.
    PubMed     Abstract available
    
    
    June 2025
52. SUN N, Hu X, Wang J, Yao T, et al
    Minichromosome Maintenance Complex Genes Are Candidate Biomarkers of Retinal Degeneration.
    J Ocul Pharmacol Ther. 2025 Jun 27. doi: 10.1089/jop.2025.0047.
    PubMed     Abstract available
    
    
    
53. WANG Q, Peng Y, Wang S, Xu J, et al
    Exploring the Efficacy of AZD6738 in Corneal Neovascularization: Autophagy Enhancement and Angiogenesis Inhibition.
    J Ocul Pharmacol Ther. 2025 Jun 27. doi: 10.1089/jop.2024.0162.
    PubMed     Abstract available
    
    
    
54. SRIKAJORN C, Tiyaboonchai W, Srinivas SP, Thongsuk W, et al
    Mucoadhesive Silk Fibroin Nanoparticles for Drug Delivery to the Ocular Surface.
    J Ocul Pharmacol Ther. 2025 Jun 24. doi: 10.1089/jop.2024.0180.
    PubMed     Abstract available
    
    
    
55. KROSSER S, Grillenberger R, Eickhoff K, Korward J, et al
    Ocular Pharmacokinetics and Biodistribution of Perfluorohexyloctane after Topical Administration to Rabbits.
    J Ocul Pharmacol Ther. 2025 Jun 19. doi: 10.1089/jop.2025.0056.
    PubMed     Abstract available
    
    
    
56. OZGUR A, Ozmen MC, Yalinbas Yeter D, Inan MA, et al
    Antineovascular Effects of Coenzyme Q10 and Vitamin E Combination in Corneal Neovascularization: A Pilot Study.
    J Ocul Pharmacol Ther. 2025 Jun 11. doi: 10.1089/jop.2025.0068.
    PubMed     Abstract available
    
    
    
57. CHU G, Wang J, Wang Z, Cai X, et al
    Autologous Serum from Sjogren's Syndrome Patients Mitigates Ferroptosis in Hyperosmolarity-Induced Corneal Epitheliopathy.
    J Ocul Pharmacol Ther. 2025 Jun 11. doi: 10.1089/jop.2025.0025.
    PubMed     Abstract available
    
    
    
58. PADMANABHAN NAIR A, Machiraju P, Tejwani S, Dinakaran S, et al
    Lower Levels of Endogenous Intraocular Interferon Beta in Patients with Primary Glaucoma.
    J Ocul Pharmacol Ther. 2025 Jun 9. doi: 10.1089/jop.2025.0085.
    PubMed     Abstract available
    
    
    
59. SUN CC, Pan LY, Chen NN, Kuo YK, et al
    Risk and Protective Factors for Ocular Surface Disease in Patients with Type 2 Diabetic Mellitus: A Retrospective Cohort Study.
    J Ocul Pharmacol Ther. 2025 Jun 9. doi: 10.1089/jop.2024.0175.
    PubMed     Abstract available
    
    
    
60. SADRI E, Verachtert A, Parkhurst GD, Echegoyen J, et al
    Durability of Treatment with a Thermomechanical Device in Meibomian Gland Dysfunction: An Observational Extension Study.
    J Ocul Pharmacol Ther. 2025;41:237-243.
    PubMed     Abstract available
    
    
    
61. DOLAN K
    Rosalind Franklin Society Proudly Announces the 2024 Award Recipient for Journal of Ocular Pharmacology and Therapeutics.
    J Ocul Pharmacol Ther. 2025;41:229.
    PubMed    
    
    
    May 2025
62. ROY A, Kompella UB
    Rose Bengal-Assisted Photodynamic Antimicrobial Therapy for Keratitis.
    J Ocul Pharmacol Ther. 2025 May 29. doi: 10.1089/jop.2025.0010.
    PubMed     Abstract available
    
    
    
63. LACAU S, Marin A, Bitrian E
    Steroid-Induced Ocular Hypertension in Children: A Review on Risk Factors.
    J Ocul Pharmacol Ther. 2025 May 13. doi: 10.1089/jop.2025.0024.
    PubMed     Abstract available
    
    
    
64. AFTAB OM, Khan H, Aftab B, Haque W, et al
    Corneal Complications: Drug-Induced Deposits and Food and Drug Administration Adverse Event Reporting System Data Insights-A Retrospective Study.
    J Ocul Pharmacol Ther. 2025 May 5. doi: 10.1089/jop.2024.0178.
    PubMed     Abstract available
    
    
    
65. SHARMA A, Sharma PK, Kompella UB
    Lotilaner for Demodex Blepharitis: The Journey from Veterinary Use to Human Medicine.
    J Ocul Pharmacol Ther. 2025;41:173-186.
    PubMed     Abstract available
    
    
    
66. NAVARRO-NARANJO PI, Chacon-Aponte A, Artunduaga-Rodriguez G
    Clinical Results of the Use of a Combined Solution of 0.5% Carboxymethylcellulose, 0.9% Glycerin, and 3% Trehalose for the Treatment of Dry Eye Disease.
    J Ocul Pharmacol Ther. 2025;41:210-216.
    PubMed     Abstract available
    
    
    April 2025
67. FAHMY A, Ahmed M, Pflugfelder S, Serikbaeva A, et al
    Comparative Efficacy of Current Topical Treatments for Dry Eye Disease: A Review of Pivotal Clinical Trials Evaluating Corneal Staining Outcomes.
    J Ocul Pharmacol Ther. 2025 Apr 28. doi: 10.1089/jop.2024.0192.
    PubMed     Abstract available
    
    
    
68. LIU J, Jiang E, Kim H, Moon J, et al
    Beneficial Effect of Rebamipide Eye Drops on Blue Light-Induced Oxidative Damage in the Ocular Surface.
    J Ocul Pharmacol Ther. 2025 Apr 28. doi: 10.1089/jop.2024.0208.
    PubMed     Abstract available
    
    
    
69. SANCHEZ-TOCINO H, Villanueva Gomez A, Saldana Burgos R, Hata Viveiros MM, et al
    Myopia Progression Study Comparing Low-Dose (0.01%) Atropine Eye Drops with a Control Group.
    J Ocul Pharmacol Ther. 2025 Apr 18. doi: 10.1089/jop.2024.0202.
    PubMed     Abstract available
    
    
    
70. QUIRKE M, Lamoureux F, Arnoult C, Gress G, et al
    Tacrolimus 0.1% Ophthalmic Suspension: Corneal and Intraocular Penetration Study.
    J Ocul Pharmacol Ther. 2025 Apr 18. doi: 10.1089/jop.2024.0165.
    PubMed     Abstract available
    
    
    
71. PETTY RM, Rangan RS, Curry S, Brooks CD, et al
    Biodistribution of Reconstituted High-Density Lipoprotein Nanoparticles for Targeted Delivery to Retinal Ganglion Cells.
    J Ocul Pharmacol Ther. 2025 Apr 18. doi: 10.1089/jop.2024.0191.
    PubMed     Abstract available
    
    
    
72. DUTRA BAL, Wilson SE
    Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity.
    J Ocul Pharmacol Ther. 2025 Apr 16. doi: 10.1089/jop.2024.0200.
    PubMed     Abstract available
    
    
    
73. REITINGER JC, Reed DM, Peres C, Fan S, et al
    Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol.
    J Ocul Pharmacol Ther. 2025 Apr 14. doi: 10.1089/jop.2024.0112.
    PubMed     Abstract available
    
    
    
74. JIN H, Yoon HJ, Jiang E, Liu J, et al
    Therapeutic Effects of Human Placental Extracts Eye Drops in Experimental Dry Eye and Alkali Burn.
    J Ocul Pharmacol Ther. 2025;41:141-149.
    PubMed     Abstract available
    
    
    March 2025
75. KISHI A, Bryant AD, Reed DM, Toris CB, et al
    Letter to the Editor: Effect of Aqueous Tears on Topical Fluorescein Tracer Emission Signal from Cornea and Anterior Chamber.
    J Ocul Pharmacol Ther. 2025 Mar 10. doi: 10.1089/jop.2024.0143.
    PubMed    
    
    
    
76. PUTRI LR, Edwar L
    Corticosteroid as Treatment in Infective Conjunctivitis: A Systematic Literature Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2025 Mar 10. doi: 10.1089/jop.2024.0110.
    PubMed     Abstract available
    
    
    
77. AFTAB OM, Khan H, Bargoud A, Khouri AS, et al
    Are Alpha-2 Adrenergic Agonists Being Used in Infants?
    J Ocul Pharmacol Ther. 2025;41:75-78.
    PubMed     Abstract available
    
    
    February 2025
78. ROUTH BL, Tripathi R, Giuliano EA, Lankau BR, et al
    Effect of Chemical Injury on Autophagy in Canine Corneal Stromal Fibroblasts.
    J Ocul Pharmacol Ther. 2025 Feb 17. doi: 10.1089/jop.2024.0211.
    PubMed     Abstract available
    
    
    
79. ALEKSANDER-IVANOV Y, Amaral DC, Cheidde L, Lima GN, et al
    Safety and Efficacy of 0.1% Cyclosporine Solutions in Dry Eye Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    J Ocul Pharmacol Ther. 2025 Feb 10. doi: 10.1089/jop.2024.0169.
    PubMed     Abstract available
    
    
    
80. VOUGHT R, Vought V, Crane AB, Khouri AS, et al
    Medicare Part D Glaucoma Drug Prescribing Patterns by Ophthalmologists from 2018 to 2022.
    J Ocul Pharmacol Ther. 2025 Feb 5. doi: 10.1089/jop.2024.0196.
    PubMed     Abstract available
    
    
    
81. HONG S, Woo M, Eom Y, Kim HK, et al
    A Multicenter, Randomized, Clinical Trial Assessing the Effect of rTG-Omega 3 Supplementation on Meibomian Gland Dysfunction Patients after Cataract Surgery rTG-Omega 3 for Meibomian Gland Dysfunction.
    J Ocul Pharmacol Ther. 2025 Feb 5. doi: 10.1089/jop.2024.0160.
    PubMed     Abstract available
    
    
    
82. SADIKAN MZ, Lambuk L, Reshidan NH, Abdul Ghani NA, et al
    Age-Related Macular Degeneration Pathophysiology and Therapeutic Potential of Tocotrienols: An Update.
    J Ocul Pharmacol Ther. 2025 Feb 3. doi: 10.1089/jop.2024.0123.
    PubMed     Abstract available
    
    
    January 2025
83. COSKUN A, Senturk F, Turan E
    Enhanced Transepithelial Riboflavin Delivery Across the Cornea Using Magnetic Nanocarriers.
    J Ocul Pharmacol Ther. 2025 Jan 30. doi: 10.1089/jop.2024.0183.
    PubMed     Abstract available
    
    
    
84. SARKAR T, Gogoi NR, Jana BK, Mazumder B, et al
    Formulation Advances in Posterior Segment Ocular Drug Delivery.
    J Ocul Pharmacol Ther. 2025 Jan 23. doi: 10.1089/jop.2024.0153.
    PubMed     Abstract available
    
    
    
85. CRUZ MRB, Amaral DC, Goncalves OR, Cyrino LG, et al
    Chlorhexidine Compared with Povidone-Iodine in Intravitreal Injection: A Systematic Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2025 Jan 21. doi: 10.1089/jop.2024.0141.
    PubMed     Abstract available
    
    
    
86. GRESS G, Lamoureux F, Bourgain J, Ganem A, et al
    Selective Tissue Penetration of the Corneal Layers of Cyclosporin 2% Associated with Miglyol in Rabbits.
    J Ocul Pharmacol Ther. 2025 Jan 20. doi: 10.1089/jop.2024.0087.
    PubMed     Abstract available
    
    
    
87. SADIKAN MZ, Lambuk L, Reshidan N, Ahmad Hairi H, et al
    Molecular Mechanisms of Vitamin E in Ocular Neurodegenerative Disorders: An Update on the Emerging Evidence and Therapeutic Implications.
    J Ocul Pharmacol Ther. 2025 Jan 8. doi: 10.1089/jop.2024.0125.
    PubMed     Abstract available
    
    
    
88. HOARAU G, Best AL, Zina-Meziou S, Benali-Abdallah M, et al
    Effects of Intense Pulsed Light on Presumed Neuropathic Pain Associated with Meibomian Gland Dysfunction: A Before-After Study.
    J Ocul Pharmacol Ther. 2025;41:24-32.
    PubMed     Abstract available
    
    
    December 2024
89. IRFAN AMSM, Geoffrey S, Htet H, Krishnappa P, et al
    N-Methyl-d-Aspartate-Induced Excitotoxicity and Its Impact on the Renin-Angiotensin System in Retinal Tissue.
    J Ocul Pharmacol Ther. 2024 Dec 13. doi: 10.1089/jop.2024.0131.
    PubMed     Abstract available
    
    
    
90. KOVALIS N, Graffi S, Safuri S, Shapira Y, et al
    Duration of Bare Sclera Pterygium Surgery Combined with Mitomycin C with and Without Tranexamic Acid: A Randomized Double-Blind Controlled Trial.
    J Ocul Pharmacol Ther. 2024;40:675-679.
    PubMed     Abstract available
    
    
    
91. YAN YL, Chang JY, Ling XR, Xue CY, et al
    Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2024;40:629-637.
    PubMed     Abstract available
    
    
    
92. WANG N, Yuan K, Yang S, Jin X, et al
    13-cis Retinoic Acid-Mediated Modulation of Human Meibomian Gland Epithelial Cells Development: Implications for In Vitro Modeling of Meibomian Gland Dysfunction.
    J Ocul Pharmacol Ther. 2024;40:659-667.
    PubMed     Abstract available
    
    
    
93. BHUJBAL S, Rupenthal ID, Steven P, Agarwal P, et al
    Inflammation in Dry Eye Disease-Pathogenesis, Preclinical Animal Models, and Treatments.
    J Ocul Pharmacol Ther. 2024;40:638-658.
    PubMed     Abstract available
    
    
    
94. SEETHARAMAN ATM, Owens CE, Gangaraju R
    Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits.
    J Ocul Pharmacol Ther. 2024;40:617-628.
    PubMed     Abstract available
    
    
    November 2024
95. ERB C, Topouzis F, Jayaram H, Allan F, et al
    Preclinical and Clinical Pharmacokinetics of a New Preservative-Free Bimatoprost 0.01% Ophthalmic Gel to Treat Glaucoma and Ocular Hypertension.
    J Ocul Pharmacol Ther. 2024 Nov 7. doi: 10.1089/jop.2024.0092.
    PubMed     Abstract available
    
    
    
96. ROWE-RENDLEMAN CL
    Regulatory Requirements of Biosimilars: Drug Development in Ophthalmology, Part 1.
    J Ocul Pharmacol Ther. 2024 Nov 4. doi: 10.1089/jop.2024.0151.
    PubMed    
    
    
    
97. NGUYEN A, Naidoo KK, Ajouz L, Xu X, et al
    Changes in Human Meibum Lipid Composition Related to the Presence and Severity of Meibomian Gland Dysfunction.
    J Ocul Pharmacol Ther. 2024;40:562-570.
    PubMed     Abstract available
    
    
    October 2024
98. HWANG JS, Song HB, Lee G, Jeong S, et al
    Extracellular Vesicles Derived from Adipose-Derived Mesenchymal Stem Cells Alleviate Apoptosis and Oxidative Stress of Retinal Pigment Epithelial Cells Through Activation of Nrf2 Signaling Pathway.
    J Ocul Pharmacol Ther. 2024 Oct 25. doi: 10.1089/jop.2024.0064.
    PubMed     Abstract available
    
    
    
99. DIBAS A, Batabyal S, Kim S, Carlson M, et al
    Efficacy of Intravitreal Multi-Characteristic Opsin (MCO-010) Optogenetic Gene Therapy in a Mouse Model of Leber Congenital Amaurosis.
    J Ocul Pharmacol Ther. 2024 Oct 23. doi: 10.1089/jop.2024.0084.
    PubMed     Abstract available
    
    
    
100. BOUHAJIB M, Tayab Z, Di Marco C, Suh DD, et al
     Clinical Pharmacokinetics of Atropine Administered Ocularly Using an Ultrasensitive Bioanalytical Assay.
     J Ocul Pharmacol Ther. 2024 Oct 4. doi: 10.1089/jop.2024.0113.
     PubMed     Abstract available
     
     
     
101. SULTAN A, Harris DL, Lam P, Whitcomb J, et al
     The Optejet Technology Minimizes Preservative-Mediated Cytotoxicity of Conjunctival Epithelial Cells Treated with Latanoprost In Vitro.
     J Ocul Pharmacol Ther. 2024 Oct 2. doi: 10.1089/jop.2024.0085.
     PubMed     Abstract available
     
     
     
102. HILL M, Andrews-Pfannkoch C, Atherton E, Knudsen T, et al
     Detection of Residual iPSCs Following Differentiation of iPSC-Derived Retinal Pigment Epithelial Cells.
     J Ocul Pharmacol Ther. 2024 Oct 2. doi: 10.1089/jop.2024.0130.
     PubMed     Abstract available
     
     
     
103. MATSUMOTO R, Obata S, Kakinoki M, Sawada O, et al
     Duration of Vascular Endothelial Growth Factor Suppression after Intravitreal Injection of Faricimab in Macaque Eyes.
     J Ocul Pharmacol Ther. 2024 Oct 2. doi: 10.1089/jop.2024.0138.
     PubMed     Abstract available
     
     
     September 2024
104. JUAN HY, Sheu SJ, Hwang DK
     Review of Janus Kinase Inhibitors as Therapies for Noninfectious Uveitis.
     J Ocul Pharmacol Ther. 2024 Sep 24. doi: 10.1089/jop.2024.0100.
     PubMed     Abstract available
     
     
     
105. LUHAR M, Viradiya R, Panjabi S, Patel G, et al
     Nanotechnology in Ocular Drug Delivery: The Potential of Polymeric Micelles as a Drug Delivery Vehicle.
     J Ocul Pharmacol Ther. 2024 Sep 12. doi: 10.1089/jop.2024.0060.
     PubMed    
     
     
     
106. TSENG KA
     Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Journal of Ocular Pharmacology and Therapeutics.
     J Ocul Pharmacol Ther. 2024;40:407.
     PubMed    
     
     
     
107. FUKUDA M, Kiyoi T, Takeda S, Sasaki Y, et al
     Preventative Effect of Topical Rebamipide Against Corneal Epithelium Disorders Caused by Diclofenac Sodium.
     J Ocul Pharmacol Ther. 2024;40:428-434.
     PubMed     Abstract available
     
     
     
108. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2024;40:408-409.
     PubMed    
     
     
     
109. ZHAO Y, Zhang X, Zhou X, Chen B, et al
     IL-22/IL-22RA1 Promotes Human Tenon's Capsule Fibroblasts Proliferation and Regulates Fibrosis Through STAT3 Signaling Pathway.
     J Ocul Pharmacol Ther. 2024;40:435-444.
     PubMed     Abstract available
     
     
     August 2024
110. GAO AY, Whaley MG, Saraf N, Bakri SJ, et al
     Survey of Dopamine Receptor D2 Antagonists as Retinal Antifibrotics.
     J Ocul Pharmacol Ther. 2024 Aug 29. doi: 10.1089/jop.2024.0006.
     PubMed     Abstract available
     
     
     
111. DURRANI AF, Momenaei B, Soni V, Tennant M, et al
     Long-Term Stability, Sterility, And Cost-Effectiveness of 0.05% Chlorhexidine Gluconate as Antisepsis for Intravitreal Injection.
     J Ocul Pharmacol Ther. 2024 Aug 22. doi: 10.1089/jop.2024.0071.
     PubMed     Abstract available
     
     
     
112. BACHARACH J, McLaurin EB, Silverstein S, Amrane M, et al
     Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.
     J Ocul Pharmacol Ther. 2024 Aug 16. doi: 10.1089/jop.2024.0029.
     PubMed     Abstract available
     
     
     
113. CREAN CS, Yeu E, Maiti S, Neervannan S, et al
     Ocular and Systemic Pharmacokinetics of Lotilaner Ophthalmic Solution, 0.25%, Following a Single Dose or Repeated Doses in Dutch-Belted Rabbits.
     J Ocul Pharmacol Ther. 2024 Aug 16. doi: 10.1089/jop.2024.0074.
     PubMed     Abstract available
     
     
     July 2024
114. WON J, Kang J, Kang W
     Comparative Ocular Pharmacokinetics of Dexamethasone Implants in Rabbits.
     J Ocul Pharmacol Ther. 2024 Jul 24. doi: 10.1089/jop.2024.0052.
     PubMed    
     
     
     
115. HAMEED SS, Bodi NE, Miller RC, Sharma TP, et al
     Neuritin 1 Drives Therapeutic Preservation of Retinal Ganglion Cells in an Ex Vivo Human Glaucoma Model.
     J Ocul Pharmacol Ther. 2024 Jul 12. doi: 10.1089/jop.2024.0041.
     PubMed     Abstract available
     
     
     
116. ZEMITIS A, Vanags J, Fan J, Klavins K, et al
     Metabolomic Disparities in Intraocular Fluid Across Varied Stages of Cataract Progression: Implications for the Analysis of Cataract Development.
     J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0067.
     PubMed     Abstract available
     
     
     
117. CHAUVIER J, Trone MC, Gain P, Ollier E, et al
     Corneal Toxicity in Patients Treated by BELANTAMAB MAFODOTIN: How to Improve and Facilitate Patients Follow-Up Using Refractive Shift?
     J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0023.
     PubMed     Abstract available
     
     
     
118. KASHIKAR R, Senapati S, Dudhipala N, Basu SK, et al
     Ophthalmic Nanoemulsion Fingolimod Formulation for Topical Application.
     J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0055.
     PubMed     Abstract available
     
     
     
119. DOLAN K, Liao SM, Crowley M, Xiang C, et al
     Complement Factor B Inhibition or Deletion Is Not Sufficient to Prevent Neurodegeneration in a Murine Model of Glaucoma.
     J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0046.
     PubMed     Abstract available
     
     
     
120. ZOR KR, Yilmaz U, Bozkurt SB
     Coenzyme Q10 and Vitamin E Regulate the Bioactivity of Human Corneal Fibroblast Cells.
     J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0050.
     PubMed     Abstract available
     
     
     
121. MENG C, Wei Q, Gu C, He S, et al
     Prevalence and Risk Factors of Ocular Demodex at Ultra-High Altitude and Sea Level: A Cross-Sectional Study of Shigatse and Shanghai.
     J Ocul Pharmacol Ther. 2024 Jul 4. doi: 10.1089/jop.2024.0038.
     PubMed     Abstract available
     
     
     
122. PAGNACCO C, Tosi R, Dalsaso J, Fraccaroli S, et al
     A Prospective, Randomized, Controlled Clinical Investigation Comparing the Efficacy and Safety of Sodium Hyaluronate-Based Ophthalmical Viscosurgical Devices FIDIAL PLUS and IAL((R))-F in Cataract Surgery.
     J Ocul Pharmacol Ther. 2024 Jul 1. doi: 10.1089/jop.2024.0044.
     PubMed     Abstract available
     
     
     
123. YAO Q, Wu H, Ren H, Cao J, et al
     Inhibition of Experimental Corneal Neovascularization by the Tight Junction Protein ZO-1.
     J Ocul Pharmacol Ther. 2024;40:379-388.
     PubMed     Abstract available
     
     
     
124. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2024;40:325-326.
     PubMed    
     
     
     
125. MICHAEL E, Singh V
     Diagnostic Uses of Common Eye Drops.
     J Ocul Pharmacol Ther. 2024;40:327-331.
     PubMed     Abstract available
     
     
     June 2024
126. KLEINMAN D, Iqbal S, Ghosh AK, Ogle SD, et al
     PLL-g-PEG Polymer Inhibits Antibody-Drug Conjugate Uptake into Human Corneal Epithelial Cells In Vitro.
     J Ocul Pharmacol Ther. 2024 Jun 27. doi: 10.1089/jop.2024.0019.
     PubMed     Abstract available
     
     
     
127. VARDAR C, George-Weinstein M, Getts R, Byrne ME, et al
     Evaluation of Dose-Response Relationship in Novel Extended Release of Targeted Nucleic Acid Nanocarriers to Treat Secondary Cataracts.
     J Ocul Pharmacol Ther. 2024 Jun 20. doi: 10.1089/jop.2024.0024.
     PubMed     Abstract available
     
     
     
128. LIU L, Wang S, Blanco T, Ge H, et al
     Neurokinin-1 Receptor Antagonism Reduces Nonallergic Ocular Redness in a Rabbit Model.
     J Ocul Pharmacol Ther. 2024 Jun 3. doi: 10.1089/jop.2024.0003.
     PubMed     Abstract available
     
     
     
129. LEE SS, Nagar S, Rajagopalan L, Orilla W, et al
     Using a Novel, Subconjunctival, Sustained-Release Mitomycin C Formulation in a Rabbit Model of Filtration Surgery with Gel Stent Implantation.
     J Ocul Pharmacol Ther. 2024;40:297-308.
     PubMed     Abstract available
     
     
     
130. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2024;40:259-260.
     PubMed    
     
     
     May 2024
131. ANDERSON SG, Meyer D, Decloedt EH
     The Ocular Penetration and Intraocular Pressure Lowering Effect of Topical Acetaminophen in the New Zealand White Rabbit.
     J Ocul Pharmacol Ther. 2024 May 27. doi: 10.1089/jop.2024.0020.
     PubMed     Abstract available
     
     
     
132. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2024;40:203.
     PubMed    
     
     
     April 2024
133. GUO M, Liu T, Miao Y, Pan X, et al
     Role of NADPH Oxidase 4 on Dry Eye Syndrome in Mice.
     J Ocul Pharmacol Ther. 2024 Apr 26. doi: 10.1089/jop.2024.0002.
     PubMed     Abstract available
     
     
     
134. NERI P, Perez Y, Agarwal A, Pichi F, et al
     Unraveling the Complexities of Severe Acute Respiratory Syndrome Coronavirus 2: A Comprehensive Ophthalmic and Systemic Perspective.
     J Ocul Pharmacol Ther. 2024 Apr 25. doi: 10.1089/jop.2024.0037.
     PubMed     Abstract available
     
     
     
135. BISEN AC, Srivastava S, Mishra A, Sanap SN, et al
     Pharmaceutical Emulsions: A Viable Approach for Ocular Drug Delivery.
     J Ocul Pharmacol Ther. 2024 Apr 23. doi: 10.1089/jop.2023.0166.
     PubMed     Abstract available
     
     
     
136. ANAM A, Liu C, Tong L, Liu YC, et al
     Blood-Derived Eye Drops for the Treatment of Corneal Neuropathic Pain.
     J Ocul Pharmacol Ther. 2024 Apr 22. doi: 10.1089/jop.2023.0155.
     PubMed     Abstract available
     
     
     
137. GONZALEZ VH, Uram M, Schupp A, Widmann M, et al
     AG-920 (Articaine) Ophthalmic Solution: A Masked, Active-Controlled Evaluation of Its Local Anesthetic Efficacy and Safety in Pediatric Patients.
     J Ocul Pharmacol Ther. 2024 Apr 22. doi: 10.1089/jop.2023.0187.
     PubMed     Abstract available
     
     
     
138. TRAN HDM, Ha TTX, Tran YH, Coroneo M, et al
     Impact of Various Concentrations of Low-Dose Atropine on Pupillary Diameter and Accommodative Amplitude in Children with Myopia.
     J Ocul Pharmacol Ther. 2024 Apr 15. doi: 10.1089/jop.2023.0173.
     PubMed     Abstract available
     
     
     
139. HUSAIN S, Obert E, Singh S, Schnabolk G, et al
     Inhibition of HDAC1 and 3 in the Presence of Systemic Inflammation Reduces Retinal Degeneration in a Model of Dry Age-Related Macular Degeneration.
     J Ocul Pharmacol Ther. 2024 Apr 12. doi: 10.1089/jop.2023.0163.
     PubMed     Abstract available
     
     
     
140. YADAV KS, Bisen AC, Ishteyaque S, Sharma I, et al
     Solanum nigrum Toxicity and Its Neuroprotective Effect Against Retinal Ganglion Cell Death Through Modulation of Extracellular Matrix in a Glaucoma Rat Model.
     J Ocul Pharmacol Ther. 2024 Apr 11. doi: 10.1089/jop.2023.0089.
     PubMed     Abstract available
     
     
     
141. MISHRA A, Agrawal M, Tripathi A, Bhirud A, et al
     A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension.
     J Ocul Pharmacol Ther. 2024 Apr 10. doi: 10.1089/jop.2023.0186.
     PubMed     Abstract available
     
     
     
142. DIAS PB, Rodrigues Parchen MDA, Wasilewski D
     Comparison of Proparacaine, Tetracaine, and Oxybuprocaine in Corneal Sensitivity Measurement.
     J Ocul Pharmacol Ther. 2024 Apr 8. doi: 10.1089/jop.2023.0148.
     PubMed     Abstract available
     
     
     
143. GARWEG JG, Pietzuch M, Mantel I, Ambresin A, et al
     Response to the Letter to the Editor by Michael Colucciello, MD, FASRS, Entitled "Steroid/Anti-VEGF Combination Therapy for Neovascular AMD".
     J Ocul Pharmacol Ther. 2024;40:199-200.
     PubMed    
     
     
     
144. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2024;40:158-159.
     PubMed    
     
     
     
145. WATANABE M, Sato T, Umetsu A, Nishikiori N, et al
     Differential Effects of Benzalkonium Chloride on Human Trabecular Meshwork Cells Not Treated or Treated with Transforming Growth Factor-beta2 or Dexamethasone.
     J Ocul Pharmacol Ther. 2024;40:189-196.
     PubMed     Abstract available
     
     
     
146. GAO J, Wang Y, Han R, Li J, et al
     Elevated KDM4D Expression in Pterygium: Impact and Potential Inhibition by Lycium Barbarum Polysaccharide.
     J Ocul Pharmacol Ther. 2024;40:181-188.
     PubMed     Abstract available
     
     
     March 2024
147. CHENG Y, Liu G
     Evaluation of the Treatment Effects of Conditioned Medium from Human Orbital Adipose-Derived Stem Cells in a Corneal Alkali Burn Rabbit Model.
     J Ocul Pharmacol Ther. 2024 Mar 28. doi: 10.1089/jop.2023.0154.
     PubMed     Abstract available
     
     
     
148. CID-BERTOMEU P, Vilaltella M, Martinez M, Mir M, et al
     Topical Insulin for Ocular Surface Disease.
     J Ocul Pharmacol Ther. 2024 Mar 22. doi: 10.1089/jop.2024.0016.
     PubMed     Abstract available
     
     
     
149. MURAKAMI Y, Imaizumi T, Hashizume K, Tezuka Y, et al
     Inhibition of Connective Tissue Growth Factor Expression in Adult Retinal Pigment Epithelial-19 Cells by Blocking Yes-Associated Protein/Transcriptional Coactivator with PDZ-Binding Motif Activity.
     J Ocul Pharmacol Ther. 2024 Mar 22. doi: 10.1089/jop.2023.0141.
     PubMed     Abstract available
     
     
     
150. YILMAZ OF, Sarmis A
     Relationship Between Conjunctival Corynebacterium and 5% Sheep Blood Agar.
     J Ocul Pharmacol Ther. 2024 Mar 6. doi: 10.1089/jop.2024.0010.
     PubMed    
     
     
     
151. COLUCCIELLO M
     Steroid/AntiVascular Endothelial Growth Factor Combination Therapy for Neovascular Age-Related Macular Degeneration.
     J Ocul Pharmacol Ther. 2024 Mar 6. doi: 10.1089/jop.2024.0013.
     PubMed    
     
     
     
152. LEE JH, Kim JH
     Impact of Prolonged Persisting Subretinal Fluid on the Outcome of Aflibercept Treatment in Neovascular Age-Related Macular Degeneration.
     J Ocul Pharmacol Ther. 2024;40:136-143.
     PubMed     Abstract available
     
     
     
153. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2024;40:109-110.
     PubMed    
     
     
     
154. FIGUS M, Giansanti F, Villani E, Alio JL, et al
     Chloroprocaine 3% Gel as a Novel Ocular Topical Anesthetic: Results from a Multicenter, Randomized Clinical Trial in Patients Undergoing Cataract Surgery.
     J Ocul Pharmacol Ther. 2024;40:117-125.
     PubMed     Abstract available
     
     
     February 2024
155. RUAN M, Wang R, He Y
     Novel Drug Delivery Systems for the Management of Fungal Keratitis.
     J Ocul Pharmacol Ther. 2024 Feb 23. doi: 10.1089/jop.2023.0161.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ophthalmology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum